equillium inc - EQ
EQ
Close Chg Chg %
0.87 0.00 0.11%
Closed Market
0.87
0.00 (0.11%)
Volume: 259.94K
Last Updated:
Dec 4, 2025, 4:00 PM EDT
Company Overview: equillium inc - EQ
EQ Key Data
| Open $0.89 | Day Range 0.87 - 0.92 |
| 52 Week Range 0.27 - 2.35 | Market Cap $52.98M |
| Shares Outstanding 60.89M | Public Float 43.13M |
| Beta 1.92 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.63 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 456.51K |
EQ Performance
| 1 Week | -3.42% | ||
| 1 Month | -20.77% | ||
| 3 Months | -54.37% | ||
| 1 Year | 18.80% | ||
| 5 Years | -82.21% |
EQ Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
1
Full Ratings ➔
About equillium inc - EQ
Equillium, Inc. is a clinical-stage biotechnology company that engages in the development of novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March 2017 and is headquartered in La Jolla, CA.
EQ At a Glance
Equillium, Inc.
2223 Avenida de la Playa
La Jolla, California 92037
| Phone | 1-858-240-1200 | Revenue | 41.10M | |
| Industry | Biotechnology | Net Income | -8,067,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 13.887% | |
| Fiscal Year-end | 12 / 2025 | Employees | 35 | |
| View SEC Filings |
EQ Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.644 |
| Price to Book Ratio | 1.396 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.524 |
| Enterprise Value to Sales | 0.104 |
| Total Debt to Enterprise Value | 0.09 |
EQ Efficiency
| Revenue/Employee | 1,174,142.857 |
| Income Per Employee | -230,485.714 |
| Receivables Turnover | 35.922 |
| Total Asset Turnover | 1.078 |
EQ Liquidity
| Current Ratio | 3.93 |
| Quick Ratio | 3.93 |
| Cash Ratio | 3.552 |
EQ Profitability
| Gross Margin | 99.667 |
| Operating Margin | -20.122 |
| Pretax Margin | -18.752 |
| Net Margin | -19.63 |
| Return on Assets | -21.157 |
| Return on Equity | -38.752 |
| Return on Total Capital | -41.486 |
| Return on Invested Capital | -38.228 |
EQ Capital Structure
| Total Debt to Total Equity | 2.015 |
| Total Debt to Total Capital | 1.975 |
| Total Debt to Total Assets | 1.493 |
| Long-Term Debt to Equity | 0.981 |
| Long-Term Debt to Total Capital | 0.962 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Equillium Inc - EQ
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | 15.76M | 36.08M | 41.09M | |
Sales Growth
| - | - | +128.97% | +13.89% | - |
Cost of Goods Sold (COGS) incl D&A
| 72.00K | 118.00K | 126.00K | 137.00K | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 72.00K | 118.00K | 126.00K | 137.00K | |
Depreciation
| 72.00K | 118.00K | 126.00K | 137.00K | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +60.00% | +63.89% | +6.78% | +8.73% | |
Gross Income
| (72.00K) | 15.64M | 35.96M | 40.96M | |
Gross Income Growth
| -60.00% | +21,823.61% | +129.90% | +13.91% | |
Gross Profit Margin
| - | +99.25% | +99.65% | +99.67% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 37.71M | 54.67M | 50.48M | 49.23M | |
Research & Development
| 26.38M | 37.55M | 37.04M | 37.43M | |
Other SG&A
| 11.34M | 17.12M | 13.44M | 11.80M | |
SGA Growth
| +27.83% | +44.95% | -7.66% | -2.48% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 23.05M | - |
EBIT after Unusual Expense
| (37.79M) | (62.08M) | (14.52M) | (8.27M) | |
Non Operating Income/Expense
| (193.00K) | 701.00K | 2.26M | 563.00K | |
Non-Operating Interest Income
| 57.00K | 420.00K | 2.33M | 1.38M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | 1.07M | 1.05M | 491.00K | |
Interest Expense Growth
| -2.37% | -1.86% | -53.37% | -100.00% | |
Gross Interest Expense
| - | 1.07M | 1.05M | 491.00K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (39.05M) | (62.43M) | (12.76M) | (7.71M) | |
Pretax Income Growth
| -30.99% | -59.86% | +79.57% | +39.58% | |
Pretax Margin
| - | -396.14% | -35.35% | -18.75% | |
Income Tax
| - | - | 580.00K | 361.00K | - |
Income Tax - Current - Domestic
| - | - | 580.00K | 361.00K | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (39.05M) | (62.43M) | (13.34M) | (8.07M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (39.05M) | (62.43M) | (13.34M) | (8.07M) | |
Net Income Growth
| -30.99% | -59.86% | +78.64% | +39.51% | |
Net Margin Growth
| - | -396.14% | -36.96% | -19.63% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (39.05M) | (62.43M) | (13.34M) | (8.07M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (39.05M) | (62.43M) | (13.34M) | (8.07M) | |
EPS (Basic)
| -1.3557 | -1.8509 | -0.384 | -0.2282 | |
EPS (Basic) Growth
| +7.44% | -36.53% | +79.25% | +40.57% | |
Basic Shares Outstanding
| 28.81M | 33.73M | 34.73M | 35.36M | |
EPS (Diluted)
| -1.3557 | -1.8509 | -0.384 | -0.2282 | |
EPS (Diluted) Growth
| +7.44% | -36.53% | +79.25% | +40.57% | |
Diluted Shares Outstanding
| 28.81M | 33.73M | 34.73M | 35.36M | |
EBITDA
| (37.71M) | (38.91M) | (14.40M) | (8.13M) | |
EBITDA Growth
| -27.83% | -3.17% | +63.00% | +43.51% | |
EBITDA Margin
| - | -246.90% | -39.90% | -19.79% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 1.00 | |
| Number of Ratings | 1 | Current Quarters Estimate | -0.05 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | -0.43 | |
| Last Quarter’s Earnings | -0.06 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.23 | Next Fiscal Year Estimate | -0.24 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 1 | 1 | 1 | 1 |
| Mean Estimate | -0.05 | -0.05 | -0.43 | -0.24 |
| High Estimates | -0.05 | -0.05 | -0.43 | -0.24 |
| Low Estimate | -0.05 | -0.05 | -0.43 | -0.24 |
| Coefficient of Variance | N/A | N/A | N/A | N/A |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 1 | 1 | 1 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Equillium Inc - EQ
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Equillium Inc - EQ
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Feb 20, 2025 | Barbara Troupin Director | 40,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 20, 2025 | Penny Tom Principal Accounting Officer | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Martha J. Demski Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Martha J. Demski Director | 20,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 20, 2025 | Martha J. Demski Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Martha J. Demski Director | 20,770 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 20, 2025 | Martha J. Demski Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Martha J. Demski Director | 24,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 20, 2025 | Martha J. Demski Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Martha J. Demski Director | 12,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 20, 2025 | Barbara Troupin Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Bala S. Manian Director | 12,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 20, 2025 | Bala S. Manian Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Bala S. Manian Director | 20,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 20, 2025 | Bala S. Manian Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Bala S. Manian Director | 20,770 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 20, 2025 | Bala S. Manian Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Bala S. Manian Director | 20,634 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 20, 2025 | Bala S. Manian Director | N/A | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 | 0.00 |
| Feb 20, 2025 | Bala S. Manian Director | 24,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |